lomustine and ly-2157299

lomustine has been researched along with ly-2157299 in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Azaro, A; Baselga, J; Carducci, M; Cleverly, AL; Corretti, M; Dolan, M; Fernández, MS; Gueorguieva, I; Kovacs, RJ; Lahn, MM; Maldonado, G; Pillay, NS; Romero, FL; Sepulveda-Sánchez, JM1
Azaro, A; Baselga, J; Blakeley, J; Braña, I; Calvo, E; Carducci, M; Cleverly, A; Desaiah, D; Estrem, ST; Gueorguieva, I; Holdhoff, M; Lahn, MM; Paz-Ares, L; Pillay, NS; Rodón, J; Seoane, J; Sepulveda-Sánchez, JM; Sicart, E1
Brandes, AA; Capper, D; Carpentier, AF; Cher, L; Chinot, O; Cleverly, A; Desaiah, D; Guba, SC; Gueorguieva, I; Kesari, S; Lahn, MM; Miles, C; Rodon, J; Sepulveda-Sanchez, JM; Smith, C; Specenier, P; Steinbach, JP; Wheeler, HR; Wick, W1
Brandes, AA; Capper, D; Carpentier, AF; Cher, L; Chinot, O; Cleverly, A; Desaiah, D; Estrem, ST; Guba, SC; Gueorguieva, I; Kesari, S; Lahn, MM; Miles, C; Rodon, J; Sepulveda-Sanchez, JM; Smith, C; Specenier, P; Steinbach, JP; von Deimling, A; Wheeler, HR; Wick, W1

Trials

4 trial(s) available for lomustine and ly-2157299

ArticleYear
Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study.
    Cardiovascular toxicology, 2015, Volume: 15, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Pressure; Echocardiography, Doppler; Electrocardiography; Female; Heart Diseases; Humans; Lomustine; Male; Middle Aged; Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Quinolines; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Risk Assessment; Risk Factors; Signal Transduction; Spain; Time Factors; Treatment Outcome; Young Adult

2015
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
    Investigational new drugs, 2015, Volume: 33, Issue:2

    Topics: ADAM Proteins; Adult; Aged; Anticonvulsants; Area Under Curve; Blood Cell Count; Chemokine CCL22; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Female; Humans; Leukocytes, Mononuclear; Lomustine; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Serine-Threonine Kinases; Proton Pump Inhibitors; Pyrazoles; Quinolines; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Smad2 Protein; Tumor Suppressor Proteins

2015
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
    Neuro-oncology, 2016, Volume: 18, Issue:8

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease-Free Survival; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Lomustine; Male; Middle Aged; Pyrazoles; Quinolines; Treatment Outcome

2016
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
    International journal of molecular sciences, 2017, May-06, Volume: 18, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CD4-CD8 Ratio; Cytokines; Female; Forkhead Transcription Factors; Glioblastoma; Humans; Isocitrate Dehydrogenase; Lomustine; Male; Neoplasm Recurrence, Local; Pyrazoles; Quinolines; Smad2 Protein; Survival Analysis

2017